The 2-monoacylglycerol moiety of dietary fat appears to be responsible for the fat-induced release of GLP-1 in humans1

American Journal of Clinical Nutrition

Volumn 102, Issue 3, 2015, Pages 548-555

  Mandøe, Mette J ^a,b,c   Hansen, Katrine B ^a,b,c   Hartmann, Bolette ^a   Rehfeld, Jens F ^d   Holst, Jens J ^a,b   Hansen, Harald S ^b  

^a NOVO NORDISK INC   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^d Rigshospitalet   (Denmark)

Author keywords

2 oleoyl glycerol; G protein coupled receptor 119; glucagon like peptide 1; Oleic acid; Structured triacylglycerol

Indexed keywords

1,3 DIOCTANOYL 2 OLEOYL GLYCEROL; 2 MONOACYLGLYCEROL DERIVATIVE; 2 OLEOYL GLYCEROL; BUTYRIC ACID; C PEPTIDE; CHOLECYSTOKININ; EDIBLE OIL; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LONG CHAIN FATTY ACID; MEDIUM CHAIN FATTY ACID; MONOACYLGLYCEROL; NEUROTENSIN; OCTANOIC ACID; OLEIC ACID; OLIVE OIL; PEPTIDE YY; SHORT CHAIN FATTY ACID; TRIACYLGLYCEROL; TRIBUTYRIN; UNCLASSIFIED DRUG; 2-OLEOYLGLYCEROL; ACYLGLYCEROL; FAT; FAT INTAKE; G PROTEIN COUPLED RECEPTOR; GASTROINTESTINAL HORMONE; GLUCOSE BLOOD LEVEL; GPR119 PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FAT INTAKE; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HORMONE RESPONSE; HUMAN; INSULIN BLOOD LEVEL; MALE; NORMAL HUMAN; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; STOMACH EMPTYING; TRIACYLGLYCEROL BLOOD LEVEL; ADMINISTRATION AND DOSAGE; BLOOD; CARROT; CHEMISTRY; METABOLISM; SECRETION (PROCESS); SINGLE BLIND PROCEDURE; YOUNG ADULT;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; CHOLECYSTOKININ; CROSS-OVER STUDIES; DAUCUS CAROTA; DIETARY FATS; FATS; GASTRIC EMPTYING; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONES; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLYCERIDES; HUMANS; INSULIN; MALE; MONOGLYCERIDES; NEUROTENSIN; OLEIC ACID; OLIVE OIL; PEPTIDE YY; RECEPTORS, G-PROTEIN-COUPLED; SINGLE-BLIND METHOD; TRIGLYCERIDES; YOUNG ADULT;

EID: 84941629579     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.115.106799     Document Type: Article

References (38)

1. Carr RD, Larsen MO, Winzell MS, Jelic K, Lindgren O, Deacon CF, Ahren B. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. Am J Physiol Endocrinol Metab 2008;295: E779-84.
2. Thomsen C, Rasmussen O, Lousen T, Holst JJ, Fenselau S, Schrezenmeir J, Hermansen K. Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects. Am J Clin Nutr 1999;69:1135-43.
3. Ellrichmann M, Kapelle M, Ritter PR, Holst JJ, Herzig KH, Schmidt WE, Schmitz F, Meier JJ. Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations. J Clin Endocrinol Metab 2008;93:3995-8.
4. Pilichiewicz A, O'Donovan D, Feinle C, Lei Y, Wishart JM, Bryant L, Meyer JH, Horowitz M, Jones KL. Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in type 2 diabetes mellitus. J Clin Endocrinol Metab 2003;88: 3829-34.
5. Kleberg K, Hassing HA, Hansen HS. Classical endocannabinoid-like compounds and their regulation by nutrients. Biofactors 2014;40: 363-72.
6. Mu H, Hoy CE. The digestion of dietary triacylglycerols. Prog Lipid Res 2004;43:105-33.
7. Edfalk S, Steneberg P, Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 2008;57:2280-7.
8. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S, Tsujimoto G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 2005;11:90-4.
9. Iakoubov R, Ahmed A, Lauffer LM, Bazinet RP, Brubaker PL. Essential role for protein kinase Cz in oleic acid-induced glucagon-like peptide-1 secretion in vivo in the rat. Endocrinology 2011;152:1244-52.
10. Hansen HS, Rosenkilde MM, Holst JJ, Schwartz TW. GPR119 as a fat sensor. Trends Pharmacol Sci 2012;33:374-81.
11. Hansen KB, Rosenkilde MM, Knop FK, Wellner N, Diep TA, Rehfeld JF, Andersen UB, Holst JJ, Hansen HS. 2-Oleoyl glycerol Is a GPR119 agonist and signals GLP-1 release in humans. J Clin Endocrinol Metab 2011;96:E1409-17.
12. Beglinger S, Drewe J, Schirra J, Goke B, D'Amato M, Beglinger C. Role of fat hydrolysis in regulating glucagon-like peptide-1 secretion. J Clin Endocrinol Metab 2010;95:879-86.
13. Tonack S, Tang C, Offermanns S. Endogenous metabolites as ligands for G protein-coupled receptors modulating risk factors for metabolic and cardiovascular disease. Am J Physiol Heart Circ Physiol 2013;304:H501-13.
14. Barbera R, Peracchi M, Brighenti F, Cesana B, Bianchi PA, Basilisco G. Sensations induced by medium and long chain triglycerides: role of gastric tone and hormones. Gut 2000;46:32-6.
15. Nøhr MK, Pedersen MH, Gille A, Egerod KL, Engelstoft MS, Husted AS, Sichlau RM, Grunddal KV, Poulsen SS, Han S, et al. GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes. Endocrinology 2013;154:3552-64.
16. Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, Cameron J, Grosse J, Reimann F, Gribble FM. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-proteincoupled receptor FFAR2. Diabetes 2012;61:364-71.
17. Rosqvist F, Iggman D, Kullberg J, Cedernaes J, Johansson HE, Larsson A, Johansson L, Ahlstrom H, Arner P, Dahlman I, et al. Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans. Diabetes 2014;63:2356-68.
18. Møller A. Food composition tables 1989. Søborg (Denmark): Storkøkkenet, Levnedsmiddelstyrelsen; 1989.
19. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994;43:535-9.
20. Lindgren O, Carr RD, Deacon CF, Holst JJ, Pacini G, Mari A, Ahren B. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin Endocrinol Metab 2011;96:2519-24.
21. Bablok W, Passing H, Bender R, Schneider B. A general regression procedure for method transformation: application of linear regression procedures for method comparison studies in clinical chemistry, part III. J Clin Chem Clin Biochem 1988;26:783-90.
22. Orskov C, Jeppesen J, Madsbad S, Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 1991;87:415-23.
23. Holst JJ, Pedersen JH, Baldissera F, Stadil F. Circulating glucagon after total pancreatectomy in man. Diabetologia 1983;25:396-9.
24. Baldissera FG, Holst JJ. Glucagon-related peptides in the human gastrointestinal mucosa. Diabetologia 1984;26:223-8.
25. Rehfeld JF. Accurate measurement of cholecystokinin in plasma. Clin Chem 1998;44:991-1001.
26. Heading RC, Nimmo J, Prescott LF, Tothill P. The dependence of paracetamol absorption on the rate of gastric emptying. Br J Pharmacol 1973;47:415-21.
27. Feinle C, Chapman IM, Wishart J, Horowitz M. Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men. Peptides 2002;23:1491-5.
28. Psichas A, Reimann F, Gribble FM. Gut chemosensing mechanisms. J Clin Invest 2015;125:908-17.
29. Clegg ME. Medium-chain triglycerides are advantageous in promoting weight loss although not beneficial to exercise performance. Int J Food Sci Nutr 2010;61:653-79.
30. Feltrin KL, Little TJ, Meyer JH, Horowitz M, Smout AJPM, Wishart J, Pilichiewicz AN, Rades T, Chapman IM, Feinle-Bisset C. Effects of intraduodenal fatty acids on appetite, antropyloroduodenal motility, and plasma CCK and GLP-1 in humans vary with their chain length. Am J Physiol Regul Integr Comp Physiol 2004;287:R524-33.
31. Ogawa N, Ito M, Yamaguchi H, Shiuchi T, Okamoto S, Wakitani K, Minokoshi Y, Nakazato M. Intestinal fatty acid infusion modulates food preference as well as calorie intake via the vagal nerve and midbrain-hypothalamic neural pathways in rats. Metabolism 2012;61: 1312-20.
32. Little TJ, Feltrin KL, Horowitz M, Horowitz M, Smout AJ, Rades T, Meyer JH, Pilichiewicz AN, Wishart J, Feinle-Bisset C. Doserelated effects of lauric acid on antropyloroduodenal motility, gastrointestinal hormone release, appetite, and energy intake in healthy men. Am J Physiol Regul Integr Comp Physiol 2005;289: R1090-8.
33. Persson EM, Nilsson RG, Hansson GI, Lofgren LJ, Liback F, Knutson L, Abrahamsson B, Lennernas H. A clinical single-pass perfusion investigation of the dynamic in vivo secretory response to a dietary meal in human proximal small intestine. Pharm Res 2006; 23:742-51.
34. Egerod KL, Engelstoft MS, Grunddal KV, Nohr MK, Secher A, Sakata I, Pedersen J, Windelov JA, Fuchtbauer EM, Olsen J, et al. A major lineage of enteroendocrine cells coexpress CCK, secretin, GIP, GLP-1, PYY, and neurotensin but not somatostatin. Endocrinology 2012;153: 5782-95.
35. Dockray GJ. Cholecystokinin. Curr Opin Endocrinol Diabetes Obes 2012;19:8-12.
36. Steinert RE, Feinle-Bisset C, Geary N, Beglinger C. Secretion of gastrointestinal hormones and eating control. J Anim Sci 2013;91: 1963-73.
37. Coté CD, Zadeh-Tahmasebi M, Rasmussen BA, Duca FA, Lam TK. Hormonal signaling in the gut. J Biol Chem 2014;289:11642-9.
38. Janssen S, Depoortere I. Nutrient sensing in the gut: new roads to therapeutics? Trends Endocrinol Metab 2013;24:92-100.